


COVAX UPDATE AND GAVI'S ROLE IN A FUTURE COVID-19 VACCINE PROGRAMME

BOARD MEETING

Derrick Sim, Richard Mihigo


26-27 June 2023, Geneva, Switzerland

Progression from COVAX to Gavi-supported COVID-19 programme



Increase in COVID-19 coverage

% population with complete primary series, Global vs 92 Advanced Market Commitment (AMC) entities vs 34 Countries for Concerted Support (CCS)



Gavi Alliance raised US\$ 1.6 billion and launched 3 funding windows split across CDS1, CDS2, CDS3 & other COVAX delivery support activities

July 21

CDS1: provide countries sufficient funding to **get ready for scale up of doses**

Oct 21

CDS2: support countries in covering **urgent needs and funding gaps in national plans**


June 22

CDS3 window to reach 3 objectives :

- 1) Acceleration of vaccination of **high-risk populations**
- 2) Delivery scale-up to reach country targets for **adult vaccination**
- 3) **Integration of COVID-19 and routine immunisation (RI)**

As of 07.06.2023

US\$ million



Note: **CDS1:** Early Access & first AMC 30 support / **CDS2:** CDS Needs based envelope / **CDS3:** CDS Needs based envelope third Window / **CDS3 Emergency CDS funding** managed with CoVDP & Management of AMC 30 through 3rd CDS funding window; **Committed:** amount approved for countries

RECAP | COVID-19 Vaccine Programme Investment Approach

Population cohort

- **Continued focus on the high priority user groups** as per SAGE recommendation (~20% total population)

Country scope

- Continued but **differentiated support to the AMC91** (Gavi54 and AMC37)

Co-financing and extent of support

- **Gavi54:** Eligible for **full vaccine procurement support** without co-financing obligations and delivery support (~~consisting of the provision of up to 70% of estimated total delivery costs~~) through existing CDS resources
- **AMC37:** Provide support for **50% of COVID-19 procurement costs for one year**; ~~not eligible for delivery support~~ delivery support through existing CDS resources



Based on this scope and updated assumptions, we request US\$ 711 million for 2024-2025.

Based on country demand submissions, this envelope assumes 18% coverage of the high priority groups, or 3.5% of the total AMC91 population.

- This proposal is for 2024-2025 only, after which the COVID-19 vaccine programme would be assessed alongside other antigens through the standard Gavi Vaccine Investment Strategy (VIS) process.

Key Updates since December 2022

Updated SAGE Guidance

- March 2023 SAGE recommendation confirmed the high priority user group (older adults, adults with comorbidities, immunocompromised, pregnant persons, healthcare workers) and dosing schedule

Delivery Strategy, including use of CDS

- Differentiated delivery strategy
- Delivery support through a no-cost extension of CDS

VIS-like Assessment, including impact

- Updated impact modelling shows similar outputs as December proposal
- Deaths averted per fully vaccinated person (FVP) comparable to current Gavi core routine immunisation portfolio

Updated Demand

- Country Expression of Interest (EoI) submissions from April 2023 indicate reduced demand over 2024-2025 projections (from 240 million doses to 120 million doses)

Updated Financial Envelope

- Reduced demand, no-cost extension of CDS, and dose donations result in a lower requested financial envelope (from US\$ 1.8 billion to US\$ 711 million)

Recommendation (1/2)

The Gavi Alliance Programme and Policy Committee **recommends** to the Gavi Alliance Board that it:

- a) **Approve** up to US\$ 711 million from the COVAX AMC for a new programme for COVID-19 vaccination in 2024-2025 contingent on:
 - a) Continuation of the WHO base-case scenario for the pandemic evolution requiring continued focus on high priority groups as per SAGE recommendation; and
 - b) Sufficient funding as confirmed by the Board in June 2023
- b) **Approve** the following country scope and extent of support for a 2024-2025 COVID-19 vaccine programme:
 - a) Country scope: AMC91 (Gavi54 and AMC37)
 - b) Extent of support:
 - i. Gavi54: Eligible for full vaccine procurement support without co-financing obligations and eligible for delivery support **through existing CDS resources** (~~consisting of the provision of 70% of estimated total delivery costs for the vaccines~~)
 - ii. AMC37: Eligible for vaccine catalytic financing in line with the MICs Approach for vaccine procurement and ~~not~~ eligible for delivery support **through existing CDS resources**

Recommendation (2/2)

The Gavi Alliance Board is further requested to:

- a) **Note** that Gavi will cease to administer the COVAX Facility beyond 31 December 2023, with the COVAX Facility ending in accordance with its terms on or prior to such date;
- b) **Note** that despite Gavi no longer administering the COVAX Facility beyond 31 December 2023, provision of COVID-19 vaccines would continue through Gavi per the proposed 2024-2025 COVID-19 vaccine programme, pending Board approval;
- c) **Note** that the Alliance would provide guidance on COVID-19 programmatic integration and considerations for transition to the 2024-2025 COVID-19 vaccine programme, pending Board approval, as outlined in Section 2; and
- d) **Note** that delivery funding for the 2024-2025 COVID-19 vaccine programme will be through a no-cost extension of COVID-19 Delivery Support.

Thank you